These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37864239)
21. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Keystone EC; Pope JE; Thorne JC; Poulin-Costello M; Phan-Chronis K; Vieira A; Haraoui B; Rheumatology (Oxford); 2016 Feb; 55(2):327-34. PubMed ID: 26361879 [TBL] [Abstract][Full Text] [Related]
22. Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. Radner H; Alasti F; Smolen JS; Aletaha D Arthritis Res Ther; 2015 Aug; 17(1):203. PubMed ID: 26259838 [TBL] [Abstract][Full Text] [Related]
23. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Studenic P; Aletaha D; de Wit M; Stamm TA; Alasti F; Lacaille D; Smolen JS; Felson DT Ann Rheum Dis; 2023 Jan; 82(1):74-80. PubMed ID: 36280238 [TBL] [Abstract][Full Text] [Related]
24. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638 [TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment. Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381 [TBL] [Abstract][Full Text] [Related]
26. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748 [TBL] [Abstract][Full Text] [Related]
27. Clinical conditions needed to acquire sustained functional remission in rheumatoid arthritis patients. Koizumi R; Koyama K; Wako M; Ohba T; Takayama Y; Haro H Clin Rheumatol; 2021 May; 40(5):1751-1757. PubMed ID: 33040232 [TBL] [Abstract][Full Text] [Related]
28. Predictors of Remission and Low Disease Activity in Rheumatoid Arthritis Patients: Results From the Follow-up of a Real-World Peruvian Cohort. Gamboa-Cárdenas RV; Ugarte-Gil MF; Pimentel-Quiroz V; Reátegui-Sokolova C; Rodríguez-Bellido Z; Zevallos-Miranda F; Medina-Chinchón M; Alfaro-Lozano J; Noriega-Zapata E; Cucho-Venegas JM; Perich-Campos R; Pastor-Asurza C; Alarcón GS J Clin Rheumatol; 2022 Dec; 28(8):390-396. PubMed ID: 35697014 [TBL] [Abstract][Full Text] [Related]
29. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242 [TBL] [Abstract][Full Text] [Related]
30. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Studenic P; Aletaha D; de Wit M; Stamm TA; Alasti F; Lacaille D; Smolen JS; Felson DT Arthritis Rheumatol; 2023 Jan; 75(1):15-22. PubMed ID: 36274193 [TBL] [Abstract][Full Text] [Related]
31. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H; J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689 [TBL] [Abstract][Full Text] [Related]
32. Effect of Treat-to-target Strategies Aiming at Remission of Arterial Stiffness in Early Rheumatoid Arthritis: A Randomized Controlled Study. Tam LH; Shang Q; Li EK; Wong PC; Kwok KY; Kun EW; Yim IC; Lee VK; Yip RM; Pang SH; Lao VW; Mak QW; Cheng IT; Lau XS; Li TK; Zhu TY; Lee AP; Tam LS J Rheumatol; 2018 Aug; 45(9):1229-1239. PubMed ID: 29764965 [TBL] [Abstract][Full Text] [Related]
33. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102 [TBL] [Abstract][Full Text] [Related]
34. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab. Khawaja MN; Bergman MJ; Yourish J; Pei J; Reiss W; Keystone E Arthritis Care Res (Hoboken); 2017 May; 69(5):609-615. PubMed ID: 27564431 [TBL] [Abstract][Full Text] [Related]
35. The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort. Durán J; Combe B; Niu J; Rincheval N; Gaujoux-Viala C; Felson DT Rheumatology (Oxford); 2015 Dec; 54(12):2166-70. PubMed ID: 26175470 [TBL] [Abstract][Full Text] [Related]
36. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Takeuchi T; Matsubara T; Ohta S; Mukai M; Amano K; Tohma S; Tanaka Y; Yamanaka H; Miyasaka N Rheumatology (Oxford); 2015 Apr; 54(4):683-91. PubMed ID: 25257039 [TBL] [Abstract][Full Text] [Related]
37. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort. Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821 [TBL] [Abstract][Full Text] [Related]
38. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005 [TBL] [Abstract][Full Text] [Related]
39. Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis. Shidara K; Nakajima A; Inoue E; Hoshi D; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H J Rheumatol; 2017 Feb; 44(2):147-153. PubMed ID: 27909083 [TBL] [Abstract][Full Text] [Related]
40. Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan. Yamazaki H; Hirano F; Takeuchi T; Amano K; Kikuchi J; Kihara M; Yokoyama W; Sugihara T; Nagasaka K; Hagiyama H; Nonomura Y; Sakai R; Tanaka M; Koike R; Nanki T; Kohsaka H; Miyasaka N; Harigai M Mod Rheumatol; 2017 Sep; 27(5):787-794. PubMed ID: 27846756 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]